Escherichia coli Nissle 1917 (Mutaflor): New Insights into an Old Probiotic Bacterium

Probiotic factors partially improve parameters of 5-fluorouracil-induced intestinal mucositis in rats

(2011) Luca D. Prisciandaro et al.   CANCER BIOLOGY & THERAPY

Tumor-targeted delivery of TAT-Apoptin fusion gene using Escherichia coli Nissle 1917 to colorectal cancer

(2011) Suna Zhou et al.   MEDICAL HYPOTHESES

E. coli Nissle 1917 Affects Salmonella Adhesion to Porcine Intestinal Epithelial Cells

(2011) Peter Schierack et al.   PLoS One

Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN)

(2010) Harald Matthes et al.   BMC Complementary and Alternative Medicine

Interference of Bifidobacterium choerinum or Escherichia coli Nissle 1917 with Salmonella Typhimurium in gnotobiotic piglets correlates with cytokine patterns in blood and intestine

(2010) A. Splichalova et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Probiotic Escherichia coli Nissle 1917 activates DC and prevents house dust mite allergy through a TLR4-dependent pathway

(2010) Emmanuelle Adam et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

The K5 Capsule of Escherichia coli Strain Nissle 1917 Is Important in Stimulating Expression of Toll-Like Receptor 5, CD14, MyD88, and TRIF Together with the Induction of Interleukin-8 Expression via the Mitogen-Activated Protein Kinase Pathway in Epithelial Cells

(2010) M. Hafez et al.   INFECTION AND IMMUNITY

Safety of Probiotic Escherichia coli Strain Nissle 1917 Depends on Intestinal Microbiota and Adaptive Immunity of the Host

(2010) K. Gronbach et al.   INFECTION AND IMMUNITY

Probiotic Escherichia coli strain Nissle 1917 outcompetes intestinal pathogens during biofilm formation

(2010) V. Hancock et al.   JOURNAL OF MEDICAL MICROBIOLOGY

Testing probiotic strain Escherichia coli Nissle 1917 (Mutaflor) for its ability to reduce carriage of multidrug-resistant E. coli by elderly residents in long-term care facilities

(2010) G. W. Tannock et al.   JOURNAL OF MEDICAL MICROBIOLOGY

Engineered bacterial communication prevents Vibrio cholerae virulence in an infant mouse model

(2010) F. Duan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A probiotic strain ofEscherichia coli, Nissle 1917, given orally exerts local and systemic anti-inflammatory effects in lipopolysaccharide-induced sepsis in mice

(2009) B Arribas et al.   BRITISH JOURNAL OF PHARMACOLOGY

Probiotic Escherichia coli Nissle 1917 Suppresses Allergen-Induced Th2 Responses in the Airways

(2009) Thomas Bickert et al.   INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY

Defensins and inflammation: The role of defensins in inflammatory bowel disease

(2009) Malith Ramasundara et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Probiotic Escherichia coli Nissle 1917 Versus Placebo for Treating Diarrhea of Greater Than 4 Days Duration in Infants and Toddlers

(2009) Jobst Henker et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Probiotics for the prevention of nosocomial pneumonia: current evidence and opinions

(2008) Brian McNabb et al.   CURRENT OPINION IN PULMONARY MEDICINE

Clinical use of E. coli Nissle 1917 in inflammatory bowel disease

(2008) Michael Schultz   INFLAMMATORY BOWEL DISEASES

The probiotic Escherichia coli strain Nissle 1917 induces γδ T cell apoptosis via caspase- and FasL-dependent pathways

(2008) Claudia Guzy et al.   INTERNATIONAL IMMUNOLOGY

Probiotic Escherichia coli Nissle 1917 (EcN) for Successful Remission Maintenance of Ulcerative Colitis in Children and Adolescents: an Open-Label Pilot Study 

(2008) J Henker et al.   ZEITSCHRIFT FUR GASTROENTEROLOGIE